3-吲哚基-beta-D-吡喃半乳糖苷 | 126787-65-3

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-吲哚基-beta-D-吡喃半乳糖苷
• 英文名称: (2S,3R,4S,5R,6R)-2-((1H-indol-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
• 英文别名: 1H-indol-3-yl-beta-D-galactopyranoside；3-Indoxyl-beta-D-galactopyranoside；(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-(1H-indol-3-yloxy)oxane-3,4,5-triol
• CAS: 126787-65-3
• 化学式: C₁₄H₁₇NO₆
• 分子量: 295.292
• InChiKey: XVARCVCWNFACQC-MBJXGIAVSA-N

物化性质

• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  115
• 氢给体数：
  5
• 氢受体数：
  6

安全信息

• 安全说明：
  S24/25
• 危险类别码：
  R67
• WGK Germany：
  3
• 海关编码：
  2934999090

制备方法与用途

用途

半乳糖苷酶底物

反应信息

• 作为反应物：
  描述：

  碘苯 、 3-吲哚基-beta-D-吡喃半乳糖苷 在 copper(l) iodide potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以34%的产率得到1-phenyl-1H-indol-3-yl-beta-D-galactopyranoside
  参考文献：
  名称：

  [EN] NOVEL INDICATOR PLATFORM
  [FR] NOUVELLE PLATEFORME INDICATRICE

  摘要：

  一种新颖的指示剂平台包括多种1H-吲哚-3-基指示化合物，这些化合物能够在外部刺激作用下转化为信号体化合物。在一类指示化合物中，产生的信号体是通过分子间Aldol型过程形成的2-苄基亚甲基吲哚化合物；在另一类指示化合物中，产生的信号体是通过分子内Aldol型过程形成的10H-吲哚[1,2-a]吲哚化合物。这些指示剂可用于涉及生物系统或光学数据存储等各种应用中。

  公开号：

  WO2010128120A1
• 作为产物：
  描述：

  (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-((1-acetyl-1H-indol-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以98%的产率得到3-吲哚基-beta-D-吡喃半乳糖苷
  参考文献：
  名称：

  Improved Scalable Synthesis and Biological Activity of “Indoxyl-gal,” a Chromogenic Histochemical Used for the Identification of Lac+ Organisms

  摘要：

  披露了一种改进且操作简便的3-吲哚醇-β-D-半乳糖苷（吲哚醇-半乳糖）的合成方法。吲哚醇-半乳糖是一种敏感的着色组织化学试剂，用于识别β-半乳糖苷酶的酶活性（lacZ基因）。该合成方法的改进使得从可负担的起始材料中通过5个线性步骤获得25%的总产率，并且需要最少的色谱分离。生物测试确认使用膜过滤和改良的MI琼脂，对所有（100%，19株）大肠杆菌检测到了β-半乳糖苷酶活性。

  DOI：

  10.2174/1570178615666180212152030

文献信息

• Modified enzyme and process for its preparation
  申请人：BEECHAM GROUP PLC

  公开号：EP0201153A2

  公开（公告）日：1986-11-12

  A modified tissue-type plasminogen activator comprising an amino acid without a charged side chain in place of lysine at position 277.

  一种改良的组织型纤溶酶原激活剂，其中包含一个不带电荷侧链的氨基酸，以取代第 277 位的赖氨酸。
• Fibrinolytic enzyme
  申请人：BEECHAM GROUP PLC

  公开号：EP0207589A1

  公开（公告）日：1987-01-07

  A fibrinolytically active tissue-type plasminogen activator which has been modified in the region of the growth factor domain.

  一种具有纤溶活性的组织型纤溶酶原激活剂，在生长因子结构域区域进行了修饰。
• Expression of biologically active PDGF analogs in eucaryotic cells
  申请人：ZYMOGENETICS, INC.

  公开号：EP0259632A1

  公开（公告）日：1988-03-16

  Methods for expressing a variety of biologically active PDGF analogs in eucaryotic cells are disclosed. The methods generally comprise introducing into a eucaryotic host cell a DNA construct capable of directing the expression and secretion of biologically active PDGF analogs in eucaryotic cells. The DNA construct contains a transcriptional promoter followed downstream by a suitable DNA sequence. The DNA sequence may encode a protein substantially homologous or identical to the A-chain or the B-chain of PDGF, or a portion thereof, or an A-B heterodimer. In addition, a portion of the DNA sequence may encode at least a portion of the A-chain, while another portion encodes at least a portion of the B-chain of PDGF. Eucaryotic cells transformed with these DNA constructs are also disclosed. Methods of promoting the growth of mammalian cells, comprising incubating the cells with a biologically active PDGF analog expressed by a eucaryotic host cell transformed with such a DNA construct, are also disclosed. Dimeric proteins having substantially the same biological activity as PDGF are also disclosed. More specifically, the proteins may have two polypeptide chains, one of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of the chains being substantially homologous to either the A-chain or the B-chain of PDGF, or each of the chains may be substantially identical to the A-chain of PDGF. Altematively, each of the two polypeptide chains may be a mosaic of amino acid sequences as described above. In addition, proteins comprising polypeptides that are variants or derivatives of the A- or B-chains of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.

  本发明公开了在真核细胞中表达各种生物活性 PDGF 类似物的方法。这些方法一般包括将能够引导生物活性 PDGF 类似物在真核细胞中表达和分泌的 DNA 构建体导入真核宿主细胞。DNA 构建体包含一个转录启动子，其下游是一个合适的 DNA 序列。DNA 序列可编码与 PDGF 的 A 链或 B 链基本同源或相同的蛋白质，或其一部分，或 A-B 异源二聚体。此外，DNA 序列的一部分可编码至少一部分 PDGF 的 A 链，而另一部分可编码至少一部分 PDGF 的 B 链。还公开了用这些 DNA 构建体转化的真核细胞。此外，还公开了促进哺乳动物细胞生长的方法，包括将细胞与用这种 DNA 构建体转化的真核宿主细胞表达的具有生物活性的 PDGF 类似物一起培养。 还公开了与 PDGF 具有基本相同生物活性的二聚体蛋白质。更具体地说，这些蛋白质可以有两条多肽链，其中一条多肽链是与 PDGF 的 A 链或 B 链部分基本相同的氨基酸序列的拼接，第二条多肽链与 PDGF 的 A 链或 B 链基本同源，或者每条多肽链都与 PDGF 的 A 链基本相同。或者，两条多肽链中的每一条都可以是上述氨基酸序列的混合体。此外，还公开了包含 PDGF A 链或 B 链变体或衍生物的多肽的蛋白质。还公开了含有这些蛋白质的治疗组合物和增强温血动物伤口愈合过程的方法。
• Method for mutagenesis by oligonucleotide-directed repair of a strand break
  申请人：ABBOTT LABORATORIES

  公开号：EP0319759A2

  公开（公告）日：1989-06-14

  A method for double-strand break repair and for site-directed mutagenesis in which a linear DNA molecule (target) and an oligonucleotide are cocultivated in a host cell. The oligonucleotide may have a mutation in its nucleotide sequence. The nucleotide sequence is, except for any mutation, homologous to that of the target and overlaps the nucleotide sequence at the ends of the target.

  一种用于双链断裂修复和定点诱变的方法，其中线性 DNA 分子（目标）和寡核苷酸在宿主细胞中共同培养。寡核苷酸的核苷酸序列可能有突变。除任何突变外，核苷酸序列与目标物的核苷酸序列同源，并在目标物的两端与核苷酸序列重叠。
• Method of assaying substance and immunoassay element
  申请人：KONICA CORPORATION

  公开号：EP0328106A2

  公开（公告）日：1989-08-16

  Disclosed is a method of assaying a target substance in a fluid sample. In this method, a) the target substance, b) a substance which specifically binds to the target substance, to which a biological active substance which does not bind to the target substance is attached, or to which a substance which specifically binds to a biological active substance which does not bind to the target substance is attached; c) a labelled substance which is the target substance or an analogue thereof labelled with β-D-galactosidase, or which is a substance which specifically binds to the target substance, labelled with β-D-galactosidase, d) a substance which specifically binds to the biological active substance and which does not bind to the target substance, or the biological active substance, which is fixed to a carrier, which carrier exists in a porous reaction layer of an assay element, and e) a substance which specifically binds to β-D-galactosidase and which changes a signal originated from β-D-galactosidase, which is fixed to said carrier or another carrier which exists in a porous reaction layer of an assay element are reacted and the change of the signal from β-D-galactosidase is measured.

  本发明公开了一种检测流体样品中目标物质的方法。在该方法中，a) 目标物质；b) 与目标物质特异性结合的物质，其上附有不与目标物质结合的生物活性物质，或附有与不与目标物质结合的生物活性物质特异性结合的物质；c) 标记物质，该标记物质是标记有β-D-半乳糖苷酶的目标物质或其类似物，或 是标记有β-D-半乳糖苷酶的能与目标物质特异性结合的物质； d) 能与生物活性物质特异性结合但不能与目标物质或生物活性物质结合的物质，该物 质固定在载体上、e) 一种能与β-D-半乳糖苷酶特异性结合的物质，它能改变来自β-D-半乳糖苷酶的信号，该物质固定在所述载体上或存在于检测元件多孔反应层中的另一种载体上，两者发生反应，并测量来自β-D-半乳糖苷酶的信号的变化。